Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
CLDX's Cash to Debt is ranked higher than
97% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 49.71 vs. CLDX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CLDX' s Cash to Debt Range Over the Past 10 Years
Min: 2.95  Med: 139.03 Max: No Debt
Current: No Debt
Equity to Asset 0.86
CLDX's Equity to Asset is ranked higher than
78% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CLDX: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
CLDX' s Equity to Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.83 Max: 0.94
Current: 0.86
-0.32
0.94
Interest Coverage No Debt
CLDX's Interest Coverage is ranked higher than
96% of the 367 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CLDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CLDX' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: 9999.99
Current: No Debt
N/A
9999.99
F-Score: 4
Z-Score: 2.65
M-Score: -2.71
WACC vs ROIC
19.78%
-1220.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -2131.84
CLDX's Operating margin (%) is ranked lower than
83% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -73.78 vs. CLDX: -2131.84 )
Ranked among companies with meaningful Operating margin (%) only.
CLDX' s Operating margin (%) Range Over the Past 10 Years
Min: -3414.11  Med: -493.44 Max: -13.79
Current: -2131.84
-3414.11
-13.79
Net-margin (%) -2091.08
CLDX's Net-margin (%) is ranked lower than
84% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. CLDX: -2091.08 )
Ranked among companies with meaningful Net-margin (%) only.
CLDX' s Net-margin (%) Range Over the Past 10 Years
Min: -3292.81  Med: -505.66 Max: -5.41
Current: -2091.08
-3292.81
-5.41
ROE (%) -41.41
CLDX's ROE (%) is ranked lower than
57% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -32.24 vs. CLDX: -41.41 )
Ranked among companies with meaningful ROE (%) only.
CLDX' s ROE (%) Range Over the Past 10 Years
Min: -4205.83  Med: -67.06 Max: -3.4
Current: -41.41
-4205.83
-3.4
ROA (%) -36.93
CLDX's ROA (%) is ranked lower than
60% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. CLDX: -36.93 )
Ranked among companies with meaningful ROA (%) only.
CLDX' s ROA (%) Range Over the Past 10 Years
Min: -120  Med: -42.35 Max: -2.02
Current: -36.93
-120
-2.02
ROC (Joel Greenblatt) (%) -1143.38
CLDX's ROC (Joel Greenblatt) (%) is ranked lower than
63% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. CLDX: -1143.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLDX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1156.55  Med: -530.69 Max: -10.72
Current: -1143.38
-1156.55
-10.72
Revenue Growth (3Y)(%) -33.90
CLDX's Revenue Growth (3Y)(%) is ranked lower than
81% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CLDX: -33.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CLDX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.2  Med: -10.30 Max: 71.9
Current: -33.9
-67.2
71.9
EBITDA Growth (3Y)(%) 10.40
CLDX's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CLDX: 10.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLDX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.9  Med: -2.10 Max: 22.8
Current: 10.4
-32.9
22.8
EPS Growth (3Y)(%) 8.60
CLDX's EPS Growth (3Y)(%) is ranked higher than
67% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. CLDX: 8.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLDX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -71.6  Med: -7.00 Max: 134.8
Current: 8.6
-71.6
134.8
» CLDX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CLDX Guru Trades in Q2 2015

Murray Stahl 26,335 sh (unchged)
First Eagle Investment 559,542 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Columbia Wanger 2,591,703 sh (-7.46%)
» More
Q3 2015

CLDX Guru Trades in Q3 2015

Columbia Wanger 3,109,615 sh (+19.98%)
Murray Stahl 26,335 sh (unchged)
First Eagle Investment 559,542 sh (unchged)
» More
Q4 2015

CLDX Guru Trades in Q4 2015

Paul Tudor Jones 15,857 sh (New)
Columbia Wanger 3,610,008 sh (+16.09%)
First Eagle Investment 579,542 sh (+3.57%)
Murray Stahl 26,335 sh (unchged)
» More
Q1 2016

CLDX Guru Trades in Q1 2016

John Paulson 70,800 sh (New)
Jim Simons 813,331 sh (New)
Paul Tudor Jones 139,437 sh (+779.34%)
First Eagle Investment 629,542 sh (+8.63%)
Murray Stahl 26,335 sh (unchged)
Columbia Wanger 2,976,400 sh (-17.55%)
» More
» Details

Insider Trades

Latest Guru Trades with CLDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ENTA, OTCPK:PTCHF, NAS:ARNA, NAS:RPTP, NAS:XNPT, NAS:SPPI, NAS:GERN, OTCPK:SPHDF, OTCPK:ZLDPF, NAS:OMER, OTCPK:ADOCY, NAS:CYAD, NAS:LOXO, NAS:OTIC, NAS:FLML, NAS:SGMO, NAS:WVE, NAS:GALE, NAS:GBT, NAS:VNDA » details
Traded in other countries:TCE1.Germany,
Celldex Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the development, manufacturing and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.

Celldex Therapeutics Inc was incorporated in Delaware. The Company is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Its drug candidates are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. It is using these technologies to develop targeted immunotherapeutics comprised of protein-based molecules such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. Its stage drug candidate, Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as EGFRvIII. Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate in a randomized, Phase 2b study for the treatment of triple negative breast cancer and a Phase 2 study for the treatment of metastatic melanoma. Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient's immune response against their cancer. It established proof of concept in a Phase 1 study with varlilumab, which has allowed several combination studies to begin in various indications. The Company is a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. Its clinical development programs include Rintega, Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, CDX-014. The Company relies on contract manufacturing organizations, or CMOs, to manufacture drug substance and drug product for its late-stage clinical studies of Rintega and glembatumumab vedotin as well as for future commercial supplies. It also relies on CMOs for filling and packaging, labeling, storage and shipping of drug product. The Company own or license rights under more than 300 granted patents and national and regional patent applications in the U.S. and in international territories covering inventions relating to its business. Competitors that the Company is aware of that have initiated a Phase 3 study or have obtained marketing approval for a potential competitive drug/device for Rintega in the treatment of glioblastoma and/or glembatumumab vedotin in the treatment of breast cancer include AbbVie, Arbor Pharmaceutics, Inc., AstraZeneca PLC, Bayer, Bristol-Myers Squibb, Celgene Corporation, Eisai Inc., Eli Lilly and Company, Medigene AG, Northwest Biotherapeutics, Inc., Novartis, Novocure, Pfizer Inc., and Roche.

Ratios

vs
industry
vs
history
P/B 1.64
CLDX's P/B is ranked higher than
79% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 3.34 vs. CLDX: 1.64 )
Ranked among companies with meaningful P/B only.
CLDX' s P/B Range Over the Past 10 Years
Min: 1.23  Med: 5.19 Max: 50.74
Current: 1.64
1.23
50.74
P/S 69.21
CLDX's P/S is ranked lower than
80% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. CLDX: 69.21 )
Ranked among companies with meaningful P/S only.
CLDX' s P/S Range Over the Past 10 Years
Min: 1.67  Med: 33.56 Max: 975.38
Current: 69.21
1.67
975.38
Current Ratio 10.31
CLDX's Current Ratio is ranked higher than
77% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CLDX: 10.31 )
Ranked among companies with meaningful Current Ratio only.
CLDX' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.63 Max: 17.22
Current: 10.31
0.56
17.22
Quick Ratio 10.31
CLDX's Quick Ratio is ranked higher than
78% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. CLDX: 10.31 )
Ranked among companies with meaningful Quick Ratio only.
CLDX' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.63 Max: 17.22
Current: 10.31
0.56
17.22
Days Sales Outstanding 49.09
CLDX's Days Sales Outstanding is ranked higher than
61% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. CLDX: 49.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.43  Med: 13.35 Max: 89.44
Current: 49.09
1.43
89.44

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.03
CLDX's Price/Net Cash is ranked higher than
83% of the 691 Companies
in the Global Biotechnology industry.

( Industry Median: 4.99 vs. CLDX: 2.03 )
Ranked among companies with meaningful Price/Net Cash only.
CLDX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.76  Med: 7.61 Max: 47.3
Current: 2.03
1.76
47.3
Price/Net Current Asset Value 1.96
CLDX's Price/Net Current Asset Value is ranked higher than
84% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. CLDX: 1.96 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CLDX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.7  Med: 6.88 Max: 1163
Current: 1.96
1.7
1163
Price/Tangible Book 1.86
CLDX's Price/Tangible Book is ranked higher than
78% of the 945 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. CLDX: 1.86 )
Ranked among companies with meaningful Price/Tangible Book only.
CLDX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.62  Med: 6.15 Max: 54.69
Current: 1.86
1.62
54.69
Price/Median PS Value 2.07
CLDX's Price/Median PS Value is ranked lower than
84% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. CLDX: 2.07 )
Ranked among companies with meaningful Price/Median PS Value only.
CLDX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.97 Max: 37.61
Current: 2.07
0.05
37.61
Earnings Yield (Greenblatt) (%) -74.75
CLDX's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 1100 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. CLDX: -74.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLDX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -460.4  Med: 391.85 Max: 1732
Current: -74.75
-460.4
1732

More Statistics

Revenue (TTM) (Mil) $6.30
EPS (TTM) $ -1.33
Beta2.45
Short Percentage of Float29.96%
52-Week Range $2.96 - 28.08
Shares Outstanding (Mil)98.72

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 4 3 43
EPS ($) -1.34 -1.39 -1.34
EPS w/o NRI ($) -1.34 -1.39 -1.34
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for CLDX

Headlines

Articles On GuruFocus.com
Cantor Fitzgerald and Brean Capital Positive on Celldex Therapeutics Following Positive Data For Bra Jun 01 2015 
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
CLDX up 223%, Cohen Gains Big Apr 23 2013 
Steve Cohen Increases Celldex Up 145% Apr 06 2013 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) Aug 05 2010 

More From Other Websites
Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : June... Jun 13 2016
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 09 2016
Celldex Rose on Phase 2 Melanoma Data Jun 08 2016
Celldex (CLDX) Presents Phase II Melanoma Study Data Jun 06 2016
Celldex Therapeutics' CDX‑1401, CDX‑301 Combination Generates Potent NY-ESO-1 Immune Responses... Jun 04 2016
Celldex Therapeutics’ CDX‑1401, CDX‑301 Combination Generates Potent NY-ESO-1 Immune Responses... Jun 04 2016
Immunomedics Kicked Out of Prestigious ASCO Cancer Conference Jun 03 2016
Key Movers to Look for Ahead of ASCO May 29 2016
ETF’s with exposure to Celldex Therapeutics, Inc. : May 24, 2016 May 24 2016
CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... May 19 2016
8 Stocks on the Move After ASCO Cancer Abstracts May 19 2016
Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : May... May 19 2016
Here’s Why These Five Stocks Are Gaining Ground Today May 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)